Eli Lilly And Company Announces Jardiance Recommended For The Treatment Of Adults With Chronic Kidney Disease In The EU; CHMP Of EMA Granted Positive Opinion Recommending Jardiance For Treatment Of Adults With Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly and Company announced that its drug Jardiance has been recommended for the treatment of adults with chronic kidney disease in the EU. The CHMP of EMA granted a positive opinion, recommending Jardiance for this treatment.
June 23, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Jardiance has been recommended for treating adults with chronic kidney disease in the EU, potentially expanding the drug's market.
The positive opinion from the CHMP of EMA for Jardiance's use in treating adults with chronic kidney disease in the EU is a significant development for Eli Lilly. This recommendation could lead to an expanded market for the drug, potentially increasing the company's revenues and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100